Clopidogrel for the Prevention of Exacerbations in Severe COPD
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Chronic Obstructive Pulmonary Disease (COPD) is a debilitating respiratory disorder
characterized by gradual and progressive airflow limitation. It has been hypothesized that
clopidogrel may have a role in reducing the exacerbation of COPD by reducing thromboembolic
events. Several observational studies have found that taking clopidogrel reduces the
likelihood of COPD exacerbations in patients with the disease. The study being conducted will
be a randomized control trial, from March 2023 to March 2024 in the department of
pulmonology, LRH. The aim of the study is to determine the role of clopidogrel in reducing
the frequency of exacerbation in COPD patients compared to controls. The sampling will be
done by non-probability consecutive sampling and the patients will be randomly allocated in
study and control groups. Both the groups will be followed at the 3rd, 6th, and 12th months
of the treatment and will be compared for the outcomes.